
doi: 10.3205/18gmds045
Einleitung: Seit Inkrafttreten des Arzneimittelmarkt-Neuordnungsgesetzes (AMNOG) zum 01.01.2011 ist es nach § 35a SGB V gesetzlich vorgeschrieben, dass neue Wirkstoffe nach Markteintritt durch den Gemeinsamen Bundesausschuss (G-BA) einer frühen Nutzenbewertung unterzogen werden. Dabei wird[zum vollständigen Text gelangen Sie über die oben angegebene URL]
63. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS)
ddc: 610, 610 Medical sciences; Medicine, Biometrie
ddc: 610, 610 Medical sciences; Medicine, Biometrie
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
